Sodium Valproate - Revision history

Helen: /* Drug Management */

2020-10-12T08:14:49Z

Drug Management

← Older revision		Revision as of 04:14, 12 October 2020
Line 154:		Line 154:
	===Breast-feeding===		===Breast-feeding===
	Use during breast feeding is not recommended.		Use during breast feeding is not recommended.


	===Warning===		===Warning===

Helen: /* Drug interaction */

2020-10-12T08:14:28Z

Drug interaction

← Older revision		Revision as of 04:14, 12 October 2020
Line 93:		Line 93:
	\|Enhance sodium valproate effect		\|Enhance sodium valproate effect
	\|-		\|-
	\|style="text-align: left"\|'' Antibiotics'':		\|style="text-align: left"\| Antibiotics:

	Erythromycin		Erythromycin

	Carbapenems		Carbapenems

	\|May increase plasma valproate concentration.		\|May increase plasma valproate concentration.
	\|-		\|-
	\|style="text-align: left"\| ''Antidepressant		\|style="text-align: left"\| Antidepressant
	\|Combine may cause lower seizure threshold.		\|Combine may cause lower seizure threshold.
	\|-		\|-
	\|style="text-align: left"\| ''Anticoagulants:		\|style="text-align: left"\| Anticoagulants:

	coumarins (warfarin)		coumarins (warfarin)

	\|Sodium valproate possibly increase the anticoagulant function of warfarin.		\|Sodium valproate possibly increase the anticoagulant function of warfarin.
	\|-		\|-
	\|style="text-align: left"\| ''Other anticonvulsant		\|style="text-align: left"\| Other anticonvulsant
	\|Carbamazepine reduces the plasma concentration of sodium valproate, also the plasma concentration of the active metabolite of carbamazepine increased.		\|Carbamazepine reduces the plasma concentration of sodium valproate, also the plasma concentration of the active metabolite of carbamazepine increased.
	Sodium valproate increases other anti-epileptic plasma concentration.		Sodium valproate increases other anti-epileptic plasma concentration.

	\|-		\|-
	\|style="text-align: left"\| ''Anxiolytics:		\|style="text-align: left"\| Anxiolytics:

	Clonazepam		Clonazepam

Line 132:		Line 135:
	\|}		\|}

	~~'''~~Caution		===Caution===
	*Systemic lupus erythematosus		*Systemic lupus erythematosus

	~~'''~~Contraindications		===Contraindications===
	*Severe hepatic dysfunction (family history or personal)		*Severe hepatic dysfunction (family history or personal)
	*Known mitochondrial disorder.		*Known mitochondrial disorder.
	*Acute porphyria		*Acute porphyria

	~~'''~~Hepatic impairment		===Hepatic impairment===
	Avoid if possible		Avoid if possible

	~~'''~~Renal impairment		===Renal impairment===
	Reduce dose		Reduce dose

	~~'''~~Pregnancy		===Pregnancy===
	sodium valproate is associated with congenital malformation and neurodevelopmental effects, avoid unless there was no other safer alternative.		sodium valproate is associated with congenital malformation and neurodevelopmental effects, avoid unless there was no other safer alternative.

	~~'''~~Breast-feeding		===Breast-feeding===
	Use during breast feeding is not recommended.		Use during breast feeding is not recommended.


	~~'''~~Warning:		===Warning===
			#This medicine may make you sleepy. If this happens, do not drive, use tools or machines
	1. This medicine may make you sleepy. If this happens, do not drive, use tools or machines		#Do not stop taking this medicine unless your doctor tells you to stop

	2. Do not stop taking this medicine unless your doctor tells you to stop

	== FAQ ==		== FAQ ==

Helen: /* Drug Management */

2020-10-12T08:13:03Z

Drug Management

← Older revision		Revision as of 04:13, 12 October 2020
Line 81:		Line 81:

	==Drug Management==		==Drug Management==
			===Monitoring===
	~~'''~~Monitoring:
	*Monitor liver function before therapy and during the first 6 month of treatment, espesically patient with risk.		*Monitor liver function before therapy and during the first 6 month of treatment, espesically patient with risk.
	*Measure full blood count including platelet to make sure no potential bleeding risk.		*Measure full blood count including platelet to make sure no potential bleeding risk.

	~~'''~~Drug interaction:		===Drug interaction===

	{\| class = "wikitable"		{\| class = "wikitable"
	!style="text-align: left"\| Drugs given with sodium valproate		!style="text-align: left"\| Drugs given with sodium valproate

Helen: /* Drug Management */

2020-10-12T08:12:20Z

Drug Management

← Older revision		Revision as of 04:12, 12 October 2020
Line 85:		Line 85:
	*Monitor liver function before therapy and during the first 6 month of treatment, espesically patient with risk.		*Monitor liver function before therapy and during the first 6 month of treatment, espesically patient with risk.
	*Measure full blood count including platelet to make sure no potential bleeding risk.		*Measure full blood count including platelet to make sure no potential bleeding risk.


	'''Drug interaction:		'''Drug interaction:

Helen: /* Pharmacokinetics */

2020-10-12T08:12:14Z

Pharmacokinetics

← Older revision		Revision as of 04:12, 12 October 2020
Line 65:		Line 65:

	==Pharmacokinetics==		==Pharmacokinetics==


	{\|class="wikitable"		{\|class="wikitable"
Line 80:		Line 79:
	\|Elimination half-life approximately 9-16 hours		\|Elimination half-life approximately 9-16 hours
	\|}		\|}


	==Drug Management==		==Drug Management==

Helen: /* Side Effects */

2020-10-12T08:12:01Z

Side Effects

← Older revision		Revision as of 04:12, 12 October 2020
Line 55:		Line 55:
	==Side Effects==		==Side Effects==
	Common side effects include:		Common side effects include:

	Aggression behaviour, anaemia, confusion, convulsion, deafness, diarrhoea, extrapyramidal disorder, gastric irritation, haemorrhage, headache,hyponatremia , memory impairment, menstrual disturbance, nausea, nystagmus, sedation, stupor, thrombocytopenia, transient hair loss, tremor, weight gain.		Aggression behaviour, anaemia, confusion, convulsion, deafness, diarrhoea, extrapyramidal disorder, gastric irritation, haemorrhage, headache,hyponatremia , memory impairment, menstrual disturbance, nausea, nystagmus, sedation, stupor, thrombocytopenia, transient hair loss, tremor, weight gain.

Line 60:		Line 61:
	*Acute hepatic failure.		*Acute hepatic failure.
	*Acute pancreatitis.		*Acute pancreatitis.

	Discontinue immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, or loss of seizures control.		Discontinue immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, or loss of seizures control.


	==Pharmacokinetics==		==Pharmacokinetics==

Helen: /* Dosage */

2020-10-12T08:11:34Z

Dosage

← Older revision		Revision as of 04:11, 12 October 2020
Line 40:		Line 40:

	Administration in child:		Administration in child:

	Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg		Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg

Helen: /* Dosage */

2020-10-12T08:11:21Z

Dosage

← Older revision		Revision as of 04:11, 12 October 2020
Line 38:		Line 38:
	\|Oral:		\|Oral:
	Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily		Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily
	\|-
	Administration in child:		Administration in child:
	\|Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg		Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg

	Child 12-17 years: initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily		Child 12-17 years: initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily

Helen: /* Dosage */

2020-10-12T08:11:02Z

Dosage

← Older revision		Revision as of 04:11, 12 October 2020
Line 39:		Line 39:
	Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily		Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily
	\|-		\|-
	~~!style="text-align: left"\|~~ Administration in child:		Administration in child:
	\|Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg		\|Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg

Helen: /* Dosage */

2020-10-12T08:10:37Z

Dosage

← Older revision		Revision as of 04:10, 12 October 2020
Line 39:		Line 39:
	Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily		Initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily
	\|-		\|-
	~~{\| class="wikitable"~~
	!style="text-align: left"\| Administration in child:		!style="text-align: left"\| Administration in child:
	\|Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg		\|Child 1 month-11 years: initially 10-15 mg/kg daily in 1-2 divided doses, (max per dose 600mg.) maintenance 25-30mg/kg daily in 2 divided doses, doses up to 60mg/kg daily may be used. Monitor hematological parameters if dose exceed 40mg/kg
Line 45:		Line 44:
	Child 12-17 years: initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily		Child 12-17 years: initially 600 mg daily in 1-2 divided doses increase in steps of 150 -300 mg every 3 days maintenance 1-2g daily, maximum 2.5g daily
	\|-		\|-
	~~{\| class="wikitable"~~
	!style="text-align: left"\| Migraine prophylaxis:		!style="text-align: left"\| Migraine prophylaxis:
	\|Oral:		\|Oral:
	initially 200mg twice daily, increased if needed to 1.2-2.5g daily in divided dose.		initially 200mg twice daily, increased if needed to 1.2-2.5g daily in divided dose.
	\|-		\|-
	~~{\| class="wikitable"~~
	!style="text-align: left"\| Mania		!style="text-align: left"\| Mania
	\|Initially 750mg daily in 1-2 divided doses, usually dose 1-2g daily in 1-2 divided doses. Carefully monitor if dose exceed 45mg/kg		\|Initially 750mg daily in 1-2 divided doses, usually dose 1-2g daily in 1-2 divided doses. Carefully monitor if dose exceed 45mg/kg